Assessment of a new immunoassay for serological confirmation and discrimination of human T-cell lymphotropic virus infections. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Assessment of a new immunoassay for serological confirmation and discrimination of human T-cell lymphotropic virus infections.

Clin Diagn Lab Immunol. 1998 Jan;5(1):45-9. Unique Identifier : AIDSLINE MED/98115414
Zrein M; Louwagie J; Boeykens H; Govers L; Hendrickx G; Bosman F; Sablon E; Demarquilly C; Boniface M; Saman E; Innogenetics NV, Ghent, Belgium. maanzre@innogenetics.be

Abstract: The present study evaluated a new confirmatory assay for antibodies to human T-cell lymphotropic virus type 1 and 2 HTLV-1 and HTLV-2) proteins performed with serum samples from various commercial sources. The new test is a line immunoassay LIA) with a nylon membrane sensitized with the most relevant antigens of HTLVs: the envelope gp46 and gp21 as well as the gag p24 and p19 antigens, represented by either recombinant proteins or synthetic peptides. A total of 176 serum or plasma samples were tested, of which 66 were HTLV-1 positive, 72 were HTLV-2 positive, and 38 were HTLV negative; of the 38 HTLV-negative samples 23 were indeterminate by Western blotting (WB). Serially diluted samples (n = 33) from HTLV-1- and HTLV-2-infected patients were also analyzed to determine the sensitivity of the new assay. The new confirmatory assay (INNO-LIA HTLV) performed markedly better than WB assays for those samples reactive by screening. Accurate confirmation of the presence of HTLV-1 and HTLV-2 antibodies and accurate discrimination of HTLV-1 and HTLV-2 antibodies were obtained for all the HTLV-seropositive samples. Due to its enhanced specificity and sensitivity, the new assay not only improves the ability to confirm and discriminate HTLV infections but also eliminates the vast majority of WB-indeterminate and false-positive specimens.
Keywords: *HTLV-BLV Infections/BLOOD *HTLV-BLV Viruses/CLASSIFICATION *Immunoassay/METHODSKWDhtlv-blvinfections/bloodKWDhtlv-blvviruses/classificationKWDimmunoassay/methods
980630
M9861797

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .